The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2020Gene Therapy Approach to Reduce Alpha‐synuclein Aggregation in a Model of Parkinson's
Study Rationale:
A hallmark of Parkinson’s disease is the accumulation of an abnormal form of the protein alpha-synuclein inside brain cells. The team plans to use a gene therapy approach to insert a... -
Improved Biomarkers and Clinical Outcome Measures, 2020Development of a Non-Invasive Ophthalmic Diagnostic for Parkinson’s Disease
Study Rationale:
Currently, diagnosis of Parkinson’s disease relies on extensive neurological and physical examinations. A hallmark of Parkinson's is misfolded alpha-synuclein that forms aggregates... -
Therapeutic Pipeline Program, 2020Adaptive Deep Brain Stimulation for Gait Retraining in Parkinson's Disease
Study Rationale:
Walking impairment in people with Parkinson’s disease (PD) often arises from difficulties in coordinating leg movements in response to environment changes. Continuous stimulation of... -
Alpha-Synuclein Imaging, 2020PET Imaging Probe Development for Alpha-synuclein
Study Rationale:
Alpha-synuclein is a protein that can clump to form Lewy bodies and lewy neurites, which are a hallmark of Parkinson's disease. Being able to identify these clumps in living patients... -
Therapeutic Pipeline Program, 2020Pre-clinical Development of Compounds that Modulate Mitophagy through Regulation of the Mitochondrial GTPase Miro1
Study Rationale:
Evidence indicates that mitochondrial dysfunction is a significant contributor to Parkinson’s disease, with the majority of patients exhibiting a shared defect in the processing of... -
Alpha-Synuclein Imaging, 2020Alpha-Synuclein PET Tracer Discovery
Study Rationale:
The discovery of new treatments for Parkinson’s disease has been slowed by the time it takes to answer the question “did a drug work” in a clinical trial. Tests that can assess...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.